B2M and classic Hodgkin lymphoma: More than half of cHL cases are characterised by the loss of surface expression of MHC-I due to mutations in the gene encoding for Beta-2 microglobulin (β2M), thus impinging antigen presentation to CD8+ T-cells (21, 22).